Burlingame, Calif.—June 17, 2015—Collaborative Drug Discovery, provider of CDD Vault® web-based drug discovery informatics platform, announced they have been awarded a $1.5M Phase 2 SBIR grant to use the Bioassay Ontology Annotator as the foundation for a collaborative CDD ELN (Electronic Laboratory Notebook).
The Bioassay Ontology Annotator software provided a strong proof-of-concept that one could use new automation technologies for comparison of assay conditions with the accuracy of existing manual mark-up methods (see: Open Access Publication, Interview, Blog). Manual annotation of bioassay data is normally a laborious process, but when automated with Bioassay Ontology Annotator, research data can be quickly queried for complex ideas.
This SBIR grant will pave the way for a more collaborative, differentiated ELN. “Many research scientists are concerned about the limitations of their current ELN. With this grant we can now build automated annotation technologies into our platform that will advance the utility of applications like ELNs for secure collaboration and analyses.” said Barry A. Bunin, PhD, CDD CEO and the Principal Investigator (PI) on this latest grant.
The Bioassay Ontology Annotator software developed in phase 1 was well received by thought leaders wrestling with similar web-based, big data integration challenges at PubChem, ChEMBL, BioAssay Research Database (BARD) and National Center for Advancing Translational Sciences (NCATS). “We are confident this can be accomplished because of the best practices in design, development, and secure collaboration that is the strong foundation of the entire CDD Vault platform.” said Barry A. Bunin.
About this grant
The Phase 2 Small Business Innovation Research (SBIR) is part of a program to enable sharing of biological data. Award Number 2R44TR000185-02 from National Center for Advancing Translational Sciences as described on NIH Reporter supports this project. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.
About Collaborative Drug Discovery, Inc.
CDD’s (www.collaborativedrug.com) flagship product, “CDD Vault®”, is used to manage chemical registration, structure activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Recently developed products CDD Vision, CDD Models and CDD API compliment CDD Vault.
A complete list of the 58 publications from CDD can be found online on our resources page: https://www.collaborativedrug.com/pages/resources.
Media Contacts: Barry Bunin, PhD, Collaborative Drug Discovery, (650) 204-3084, email@example.com.
Translated with Google Translate